物质使用障碍患者的COVID-19风险与结局:美国电子健康记录分析
基于美国7309万余例电子健康记录回顾性病例对照研究,近期诊断物质使用障碍(SUD)者COVID-19风险显著升高(AOR=8.699),阿片类使用障碍(OUD)风险最高(AOR=10.244)。SUD患者COVID-19死亡(9.6%)和住院(41.0%)结局较一般COVID-19患者更差,非裔美国人风险与不良结局更显著。
要点
- 近期诊断SUD者COVID-19风险显著增加,OUD风险最高(AOR=10.244)。
- SUD患者COVID-19死亡9.6%、住院41.0%,高于一般COVID-19患者。
- 非裔美国人SUD患者COVID-19风险及不良结局高于白人。
核心结论
- 近期诊断SUD者COVID-19风险显著升高,OUD风险最高,非裔美国人风险与不良结局更显著。
研究设计与样本
- 基于美国电子健康记录(EHRs)的回顾性病例对照研究,纳入73099850例独特患者,其中12030例诊断为COVID-19。
主要发现
- 近期诊断SUD者COVID-19风险显著增加(AOR=8.699 [8.411-8.997],P<10^-30)。
- OUD患者COVID-19风险最高(AOR=10.244 [9.107-11.524],P<10^-30),其次为烟草使用障碍(TUD)(AOR=8.222 [7.925-8.530],P<10^-30)。
- SUD患者慢性肾脏、肝脏、肺部疾病、心血管疾病、2型糖尿病、肥胖和癌症患病率显著高于无SUD患者。
- 近期诊断SUD者中,非裔美国人COVID-19风险显著高于白人(AOR=2.173 [2.01-2.349],P<10^-30),OUD效应最强(AOR=4.162 [3.13-5.533],P<10^-25)。
- COVID-19合并SUD患者死亡9.6%、住院41.0%,高于一般COVID-19患者(死亡6.6%、住院30.1%)。
关键数值与推荐
- 近期诊断SUD者COVID-19风险AOR=8.699 [8.411-8.997],P<10^-30。
- OUD患者COVID-19风险AOR=10.244 [9.107-11.524],P<10^-30。
- TUD患者COVID-19风险AOR=8.222 [7.925-8.530],P<10^-30。
- 非裔美国人SUD患者COVID-19风险AOR=2.173 [2.01-2.349],P<10^-30;OUD患者AOR=4.162 [3.13-5.533],P<10^-25。
- COVID-19合并SUD患者死亡9.6%、住院41.0%;非裔美国人死亡13.0%、住院50.7%,白人死亡8.6%、住院35.2%。
临床怎么用
- 应将SUD患者(尤其OUD和非裔美国人)纳入COVID-19筛查和治疗的优先策略,并确保医疗支持可及性无差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The global pandemic of COVID-19 is colliding with the epidemic of opioid use disorders (OUD) and other substance use disorders (SUD) in the United States (US). Currently, there is limited data on risks, disparity, and outcomes for COVID-19 in individuals suffering from SUD. This is a retrospective case-control study of electronic health records (EHRs) data of 73,099,850 unique patients, of whom 12,030 had a diagnosis of COVID-19. Patients with a recent diagnosis of SUD (within past year) were at significantly increased risk for COVID-19 (adjusted odds ratio or AOR = 8.699 [8.411-8.997], P < 10-30), an effect that was strongest for individuals with OUD (AOR = 10.244 [9.107-11.524], P < 10-30), followed by individuals with tobacco use disorder (TUD) (AOR = 8.222 ([7.925-8.530], P < 10-30). Compared to patients without SUD, patients with SUD had significantly higher prevalence of chronic kidney, liver, lung diseases, cardiovascular diseases, type 2 diabetes, obesity and cancer. Among patients with recent diagnosis of SUD, African Americans had significantly higher risk of COVID-19 than Caucasians (AOR = 2.173 [2.01-2.349], P < 10-30), with strongest effect for OUD (AOR = 4.162 [3.13-5.533], P < 10-25). COVID-19 patients with SUD had significantly worse outcomes (death: 9.6%, hospitalization: 41.0%) than general COVID-19 patients (death: 6.6%, hospitalization: 30.1%) and African Americans with COVID-19 and SUD had worse outcomes (death: 13.0%, hospitalization: 50.7%) than Caucasians (death: 8.6%, hospitalization: 35.2%). These findings identify individuals with SUD, especially individuals with OUD and African Americans, as having increased risk for COVID-19 and its adverse outcomes, highlighting the need to screen and treat individuals with SUD as part of the strategy to control the pandemic while ensuring no disparities in access to healthcare support.
引用
- Wang QQ, Kaelber DC, Xu R, et al. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2020. PMID: 32929211. doi:10.1038/s41380-020-00880-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。